Junji Suzumiya

Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study

Motoko Yamaguchi, Yok‐Lam Kwong, Won Seog Kim et al. · Journal of Clinical Oncology · 2011 · 602 citations

Pharmacy, Oncology, Pharmacotherapy +13

Age-Related EBV-Associated B-Cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: A Study of 96 Patients

Takashi Oyama, Kazuhito Yamamoto, Naoko Asano et al. · Clinical Cancer Research · 2007 · 459 citations

Medicine, Hematology, Pathology +15

Senile EBV+ B-Cell Lymphoproliferative Disorders

Takashi Oyama, Koichi Ichimura, Ritsuro Suzuki et al. · The American Journal of Surgical Pathology · 2003 · 397 citations

Medicine, Hematology, Pathology +13

Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Michinori Ogura, Takashi Ishida, Kiyohiko Hatake et al. · Journal of Clinical Oncology · 2014 · 361 citations · Full text

Medicine, Oncology, Pharmacology +17

Treatment and survival among 1594 patients with ATL

Hiroo Katsuya, Kenji Ishitsuka, Atae Utsunomiya et al. · Blood · 2015 · 310 citations · Full text

Medicine, Oncology, Medical Oncology +1